Serotonergic targets in depression

被引：76

作者：

Middlemiss, DN ^{[1
]}

Price, GW ^{[1
]}

Watson, JM ^{[1
]}

机构：

[1] GlaxoSmithKline, Psychiat Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2002年 / 2卷 / 01期

关键词：

D O I：

10.1016/S1471-4892(01)00116-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Serotonin reuptake inhibitors have proved to be a very effective treatment for depression and have strengthened the hypothesis that impaired 5-hydroxytryptamine (5-HT) neurotransmission may contribute to the underlying cause of depressive disorders. Extensive research has been carried out to investigate other 5-HT targets associated with the disease and studies involving combination treatments with selective serotonin reuptake inhibitors and 5-HT1A receptor ligands are currently being carried out in the clinic. Whether other 5-HT receptor subtypes are involved in the aetiology of depression remains to be seen.

引用

页码：18 / 22

页数：5

共 53 条

[1] DECREASED PLASMA TRYPTOPHAN CONCENTRATION IN MAJOR DEPRESSION - RELATIONSHIP TO MELANCHOLIA AND WEIGHT-LOSS [J].

ANDERSON, IM ;

PARRYBILLINGS, M ;

NEWSHOLME, EA ;

POORTMANS, JR ;

COWEN, PJ .

JOURNAL OF AFFECTIVE DISORDERS, 1990, 20 (03) :185-191

[2] Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study [J].

Appelberg, BG ;

Syvälahti, EK ;

Koskinen, TE ;

Mehtonen, OP ;

Muhonen, TT ;

Naukkarinen, HH .

JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :448-452

[3]

ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248

[4] CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].

BLIER, P ;

DEMONTIGNY, C .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226

[5] Depression and sleep disorders:: Clinical relevance, economic burden and pharmacological treatment [J].

Brunello, N ;

Armitage, R ;

Feinberg, I ;

Holsboer-Trachsler, E ;

Léger, D ;

Linkowski, P ;

Mendelson, WB ;

Racagni, G ;

Saletu, B ;

Sharpley, AL ;

Turek, F ;

Van Cauter, E ;

Mendlewicz, J .

NEUROPSYCHOBIOLOGY, 2000, 42 (03) :107-119

[6] Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex [J].

Casanovas, JM ;

Hervás, I ;

Artigas, F .

NEUROREPORT, 1999, 10 (07) :1441-1445

[7] BIOCHEMISTRY OF AFFECTIVE DISORDERS [J].

COPPEN, A .

BRITISH JOURNAL OF PSYCHIATRY, 1967, 113 (504) :1237-+

[8] Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat [J].

Czachura, JF ;

Rasmussen, K .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 362 (03) :266-275

[9] The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT:: the mechanism of action of (±)pindolol [J].

Dawson, LA ;

Nguyen, HQ .

NEUROPHARMACOLOGY, 2000, 39 (06) :1044-1052

[10] Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex:: augmentation via 5-HT1A receptor antagonism [J].

Dawson, LA ;

Nguyen, HQ ;

Geiger, A .

NEUROPHARMACOLOGY, 1999, 38 (08) :1153-1163

← 1 2 3 4 5 6 →